Enrollment has begun for a Phase 1 clinical study of Acorda Therapeutics’ CVT-427 zolmitriptan DPI for the treatment of migraines, the company said. The single ascending dose study, which is expected to enroll 32 healthy adults, will assess the safety and tolerability of four doses of CVT-427 and will compare the pharmacokinetics of the inhaled drug to the pharmacokinetics of Zomig zolmitriptan tablets and nasal spray.
Acorda is developing CVT-427 with the ARCUS dry powder particle engineering and delivery technology the company acquired in 2014 when it acquired Civitas Therapeutics.
Acorda Executive Director, Device and Program Management, Sean Plunkett commented, “CVT-427 represents an innovative approach to acute treatment of migraines. Applying Acorda’s proprietary ARCUS technology, we have developed an inhaled version of a well-established migraine therapy. We are excited about evaluating the potential of CVT-427 to offer a unique way to treat people with migraine who are not completely satisfied with their current options.”
Read the Acorda Therapeutics press release.
